nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-0C011F50·Framework v5.0·Pipeline v0.4·Evaluated 05 Jun 2026·OECD: 3.1 Basic medicine·Subfield: Neurology·Basis: Full text·Type: Laboratory experiment

Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease.

De Schepper et al.De Schepper, Ge, Sierksma et al.·2023·Nature neuroscience·10.1038/s41593-023-01257-z ↗

In brief

Identifies perivascular macrophage-derived SPP1 as an upstream driver of microglial synaptic engulfment in Alzheimer's mouse models, constrained by an untested translation gap to human therapy.

ReliabilityCaveats4 of 4 checks completeCorrection published 17 Feb 2026Read the 2 entries ↓
Abstract

Alzheimer's disease (AD) is characterized by synaptic loss, which can result from dysfunctional microglial phagocytosis and complement activation. However, what signals drive aberrant microglia-mediated engulfment of synapses in AD is unclear. Here we report that secreted phosphoprotein 1 (SPP1/osteopontin) is upregulated predominantly by perivascular macrophages and, to a lesser extent, by perivascular fibroblasts. Perivascular SPP1 is required for microglia to engulf synapses and upregulate phagocytic markers including C1qa, Grn and Ctsb in presence of amyloid-β oligomers. Absence of Spp1 expression in AD mouse models results in prevention of synaptic loss. Furthermore, single-cell RNA sequencing and putative cell-cell interaction analyses reveal that perivascular SPP1 induces microglial phagocytic states in the hippocampus of a mouse model of AD. Altogether, we suggest a functional role for SPP1 in perivascular cells-to-microglia crosstalk, whereby SPP1 modulates microglia-mediated synaptic engulfment in mouse models of AD.

Strengths · Limitations

Strengths

#methodological rigour

Orthogonal methods converge on one conclusion

STED super-resolution imaging, correlative light-electron microscopy, single-molecule FISH, single-cell RNA sequencing, genetic knockouts, and in vitro rescue all triangulate the same causal chain from perivascular SPP1 to microglial engulfment.

↳ Figs. 1-5 and Extended Data Figs. 1-6

#contribution

Identifies a new cellular source of SPP1

The work localizes SPP1 predominantly to perivascular macrophages rather than microglia in the adult hippocampus, a reassignment supported by reporter mice, CLEM, and RiboTag data, reframing a known AD marker as an upstream functional signal.

↳ Results (SPP1 is expressed by PVMs and fibroblasts); Fig. 2

#contribution

Genetic necessity demonstrated with synapse rescue

Crossing Spp1 knockout to the AppNL-F model prevents microglial phagocytic marker upregulation and rescues synapse loss despite amyloid challenge, and extracellular SPP1 restores engulfment in knockout microglia, supporting an extrinsic signaling mechanism.

↳ Fig. 4 and Extended Data Figs. 4-5

Limitations

#methodological rigour

Small sample sizes in key experiments

Several pivotal readouts rest on low animal numbers, including n=2 for one Homer1 engulfment quantification and n=3 from a single independent experiment for the STED SPP1 measurement, which limits statistical confidence in individual findings.

↳ Fig. 1e,f; Fig. 3h; Fig. 5e

#methodological rigour

Computational network analysis is predictive only

The NicheNet ligand-target predictions are based on sparse sorted-cell numbers (around 200 PVMs and 350 PVFs per genotype) and Spp1 was not even detected in the sorted PVMs; only select hits are orthogonally validated, so the network claims carry substantial uncertainty.

↳ Fig. 5; Methods (scRNA-seq library preparation)

#application pathway

Translation to human disease untested

Human evidence is limited to descriptive postmortem perivascular SPP1 localization with no functional or pharmacological validation, and no therapeutic intervention targeting SPP1 is tested, leaving a substantial gap between mouse genetics and clinical utility.

↳ Fig. 1j, Fig. 2i; Discussion

Does this match your read? Add your assessment ↓

Nabu Commentary

Evaluations converged on the view that this is a competently executed, multi-modal mechanistic study whose central claim is well-supported by orthogonal methods and a clean genetic loss-of-function rescue. Divergence centered on how heavily to weight the small per-experiment sample sizes in the imaging and engulfment readouts (for example n=2 in Fig. 3h and n=3 from one experiment in Fig. 1e,f) and the predictive-only nature of the NicheNet analysis, which is built on very few sorted perivascular cells. These located limitations held the Methodological Rigour score just below the upper band despite the genuine breadth of the methodology. On impact, the genetic demonstration is meaningful but the absence of any pharmacological test and the confinement to hippocampal CA1, together with descriptive-only human data, anchor the impact assessment in the preliminary range. The Discussion's generalization toward conserved, disease-general crosstalk modestly tempered the context assessment.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.0±0.1

Contribution
4.1

The score reflects a genuine conceptual advance: identifying perivascular macrophages (not microglia) as the predominant brain source of SPP1 and showing that genetic Spp1 ablation prevents synaptic loss despite amyloid challenge. The advance is proportionate to the loss-of-function evidence and reframes SPP1 from a disease-associated marker to a functional upstream signal.

Results (SPP1 expressed by PVMs and fibroblasts; SPP1 drives microglial engulfment); Fig. 2, Fig. 4h

Absence of Spp1 expression in AD mouse models results in prevention of synaptic loss

Methodological Rigour
3.9

The score reflects a strong multi-modal design (STED, CLEM, smFISH-IHC, scRNA-seq, genetic knockouts, in vitro rescue) with appropriate statistical handling, offset by small per-experiment sample sizes in several key readouts and a predictive-only computational component. The convergence of orthogonal methods partially mitigates the limited statistical power of individual experiments.

Fig. 1e,f (n=3, one experiment); Fig. 3h (n=2 animals); Fig. 5e (n=3, one experiment); Methods (Statistics)

total of n = 3 mice examined over one independent experiment

Reporting
4.1

The score reflects a logically ordered narrative from perivascular localization through genetic perturbation to network analysis, with disciplined qualifying language for predictive findings. The only friction is the four-genotype comparison scheme, which is inherent to the design rather than a writing failure.

Results structure throughout; Discussion

we suggest a functional role for SPP1 in perivascular cells-to-microglia crosstalk

Positioning
3.9

The score reflects substantive engagement with the literature on microglial phagocytosis, complement, SPP1 biology, and perivascular cell identity, with acknowledged limitations and future directions. It is tempered by Discussion passages that generalize toward conserved, disease-general crosstalk beyond the directly tested models.

Discussion, paragraphs 1-4

SPP1 activation might represent a conserved molecular response to perturbed perivascular homeostasis

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The paper is internally consistent across abstract, figures, and results, with multiple orthogonal methods converging on the same conclusion and the scRNA-seq vs smFISH/RiboTag Spp1 detection discrepancy explicitly explained as an isolation artifact. The one noted item is that Discussion passages generalize from mouse-model findings toward broader AD-relevant and disease-general crosstalk beyond the directly tested evidence.

Research ConductNoted

Ethics approvals are declared for animal work (UK Home Office/UCL, Jackson Laboratory IACUC, Weizmann Institute Animal Care Committee) and human postmortem tissue (NHS ethics committee, license 12,198; Queen Square Brain Bank with informed consent). These are declared-but-unverified at the editorial layer; no undisclosed COI was identified; data is shared only via linked source files with no named repository and no project-specific code, which is the noted item.

Flags: 2 declared / 5 total

Reference IntegrityClean

All 85 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Correction published 17 Feb 2026 · listed in Crossref

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsFWCI 34.6
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The mechanism was pinned down in controlled mouse experiments (genetic ablation, acute oligomer challenge, primary cultures), with only observational corroboration in postmortem human tissue.

From the paper
“may offer opportunities to specifically manipulate and block microglia-mediated synaptic engulfment”

The discussion names a possible therapeutic use of the findings, blocking SPP1-mediated synaptic engulfment, but does not name who would act on them or in what setting.

Pathway

Drug developers could target perivascular SPP1 signaling to prevent microglia-mediated synaptic loss in Alzheimer's disease patients.

Barrier

The functional evidence is confined to mouse models, with no demonstration in humans that blocking SPP1 prevents synapse loss or benefits cognition.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Early Regional Microglial Remodelling in the Hippocampus of the AppAlzheimer's Model

    2026 · Basic medicine

    Primary claim

    These findings demonstrate that hippocampal microglia in App NL‐G‐F mice undergo an early, coordinated structural remodelling before local amyloid deposition becomes apparent.

    Tentative
    Evidence Score
    3.5±0.2
    Reliability
    No concerns
  2. Using iPSC models to examine neuron-glia interactions in neurodegenerative diseases

    Lopez, Keavey, Bowles · 2026 · Basic medicine

    Primary claim

    current work utilising co-culture and 3D iPSC models reveals that neuron–glial interactions in AD, PD, and primary tauopathies underlie a progressive, toxic bi-directional feed-forward cycle

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns
  3. Multiscale Approximations to Understand the Complex Role of Microglia in Alzheimer's Disease

    Martínez-Tazo, Mejias-Ortega, López-López, et al. · 2026 · Basic medicine

    Primary claim

    Microglia play a multifaceted and stage-dependent role in Aβ plaque biology, acting not only as phagocytes but also as structural regulators of plaque architecture.

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →